Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint
Dow Jones
11 hours ago
Shares of Contineum Therapeutics were trading lower after-hours Monday, following news a Phase 2 trial of an treatment for depression failed to meet its primary efficacy endpoint.
Contineum said JNJ-5120/PIPE-307 is being developed by Johnson & Johnson under a global license and development agreement. The Phase 2 Moonlight-1 trial didn't meet its primary efficacy endpoint, although the treatment was well-tolerated with no new safety signals, the company added.
Analyses of the data are ongoing, Contineum said.
After the bell, shares of Contineum were trading 8.2% lower, at $13.59. The stock ended the day's regular session flat, at $14.82.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.